ANI Pharmaceuticals (ANIP) Recalls HydrOXYzine Solution, Is The Pullback A Valuation Opportunity?
Recall event puts product quality in focus for ANI Pharmaceuticals stock
ANI Pharmaceuticals (ANIP) has voluntarily initiated a nationwide Class III recall of a specific lot of its hydrOXYzine Hydrochloride Oral Solution after detection of a foreign substance, drawing attention to its product quality controls.
See our latest analysis for ANI Pharmaceuticals.
ANI Pharmaceuticals' share price has eased in the very short term, with a 1-day share price return of 1.17% down and a 7-day share price return of 2.62% down. However, the 1-year total shareholder return of 26.75% and 5-year total shareholder return of 154.03% point to momentum that has built over time, even as investors weigh recent product quality headlines.
If you are reassessing healthcare exposure after this recall news, it can be useful to spot other businesses using AI in the sector through our 40 healthcare AI stocks
ANI Pharmaceuticals appears to be a solid operator, with revenue of $923.706 million and net income of $83.935 million. However, the share price has eased after the recall. Does that recent wobble leave the stock sensibly priced today?
Most Popular Narrative: 25.7% Undervalued
Compared with ANI Pharmaceuticals' last close at $83.78, the most widely followed narrative points to a fair value of $112.71, putting a spotlight on what assumptions are driving that gap.
Ongoing mid
and long-term investment in high-barrier-to-entry complex generics and specialty drugs as well as evidence generation (such as new clinical trials and publications) supports future pipeline expansion and portfolio diversification, bolstering both top-line growth and operating leverage.
Want to understand why this narrative sees such upside for ANI Pharmaceuticals? The core thesis leans heavily on earnings expansion, richer margins, and a future profit multiple that assumes the market will reward that profile. Curious which specific growth path and profitability targets have been built into that $112.71 figure? The full narrative unpacks the exact revenue, earnings and discount rate assumptions that sit behind this valuation call.
Result: Fair Value of $112.71 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the ANI Pharmaceuticals story could look very different if payer pushback on Cortrophin Gel limits its potential, or if generic competitors pressure margins faster than expected.
Find out about the key risks to this ANI Pharmaceuticals narrative.
Another view on ANI Pharmaceuticals valuation
While the narrative-based fair value of $112.71 suggests ANI Pharmaceuticals could be undervalued, the P/E picture is more cautious. ANIP trades on a 21.2x P/E, which is higher than the US Pharmaceuticals industry at 15.3x, although below its peer average of 39x and under the fair ratio of 24.4x. That mix of signals points to both upside and downside risk, so which one do you put more weight on?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals around ANI Pharmaceuticals' recall, quality controls, and valuation, now is a good time to review the full picture and decide where you stand using the 4 key rewards and 3 important warning signs
Looking for more investment ideas beyond ANI Pharmaceuticals?
If ANI Pharmaceuticals has you rethinking your portfolio mix, now is the time to broaden your watchlist so you do not miss other potential opportunities.
- Target resilient cash generators by scanning companies with the solid balance sheet and fundamentals stocks screener (47 results) and see which stocks pair robust financial footing with consistent fundamentals.
- Hunt for potential value gaps using the 44 high quality undervalued stocks and compare businesses that screen as higher quality yet trade at modest valuations.
- Prioritize sleep-at-night holdings through the 73 resilient stocks with low risk scores and focus on stocks that rank well on lower risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com